Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 3.3%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) shares rose 3.3% during trading on Tuesday . The company traded as high as $13.19 and last traded at $12.90. Approximately 191,207 shares changed hands during mid-day trading, a decline of 46% from the average daily volume of 355,289 shares. The stock had previously closed at $12.49.

Analyst Ratings Changes

YMAB has been the subject of a number of analyst reports. Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday, August 13th. BMO Capital Markets reduced their price target on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Truist Financial began coverage on shares of Y-mAbs Therapeutics in a research note on Friday, June 28th. They issued a “buy” rating and a $21.00 target price on the stock. Finally, Morgan Stanley decreased their price target on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research note on Tuesday, August 13th. Two equities research analysts have rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Y-mAbs Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $19.38.

Y-mAbs Therapeutics Stock Down 3.8 %

The stock has a market cap of $584.52 million, a price-to-earnings ratio of -27.37 and a beta of 0.66. The firm’s 50 day moving average is $11.92 and its two-hundred day moving average is $13.71.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Monday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. The company had revenue of $22.80 million during the quarter, compared to the consensus estimate of $23.09 million. During the same quarter in the previous year, the business posted ($0.14) earnings per share. On average, analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.55 EPS for the current fiscal year.

Insider Activity

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 35,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $12.03, for a total value of $421,050.00. Following the transaction, the insider now owns 197,681 shares in the company, valued at $2,378,102.43. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Y-mAbs Therapeutics news, insider Thomas Gad sold 35,000 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $12.03, for a total transaction of $421,050.00. Following the completion of the sale, the insider now directly owns 197,681 shares of the company’s stock, valued at $2,378,102.43. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Bo Kruse sold 31,371 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $12.07, for a total transaction of $378,647.97. Following the completion of the transaction, the chief financial officer now directly owns 210,877 shares of the company’s stock, valued at approximately $2,545,285.39. The disclosure for this sale can be found here. Insiders sold 67,093 shares of company stock worth $808,362 over the last three months. Corporate insiders own 21.50% of the company’s stock.

Institutional Trading of Y-mAbs Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of YMAB. Millennium Management LLC grew its stake in Y-mAbs Therapeutics by 23.8% in the second quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after purchasing an additional 67,233 shares in the last quarter. Squarepoint Ops LLC boosted its stake in shares of Y-mAbs Therapeutics by 143.4% during the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after acquiring an additional 74,452 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Y-mAbs Therapeutics during the 2nd quarter worth about $297,000. Dimensional Fund Advisors LP boosted its stake in shares of Y-mAbs Therapeutics by 15.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after acquiring an additional 65,732 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of Y-mAbs Therapeutics by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company’s stock worth $993,000 after acquiring an additional 2,760 shares in the last quarter. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.